December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Top Pharma Q2 2024 Earnings Results by Sabih Beck
Aug 24, 2024, 16:09

Top Pharma Q2 2024 Earnings Results by Sabih Beck

Sabih Beck shared on LinkedIn:

“Top Pharma Q2 2024 Earnings Results.

Results show ​strong performance across major companies, with a​n emphasis on innovation and expansion.

Pfizer – Strong performance, driven by improved gross margins and higher EPS guidance.

Johnson and Johnson – Strong Pharma growth but mixed performance in MedTech.

Roche – Exceeded expectations, driven by strong Pharmaceuticals and Diagnostics sectors.

Merck – Strong performance with beats in both top-line and EPS, supported by Keytruda and Winrevair.

AbbVie – Positive quarter driven by Skyrizi and Rinvoq; slight underperformance in Aesthetics.

Novartis – Consistent top-line growth with raised guidance for FY24.

Bristol Myers Squibb – Strong quarter led by Revlimid and new product launches like Camzyos.

Sanofi – Strong performance in BioPharma and Consumer Health, with some struggles in Vaccines.

AstraZeneca – Positive quarter led by strong sales in Oncology and CVRM.

GSK – Strong Specialty and General Medicines segments; slight miss in Vaccines.

Takeda – Strong Q2 performance despite some pricing pressures.

Eli Lilly and Company – Significant beat driven by Mounjaro and Zepbound.

Gilead Sciences – Solid quarter with revenue and EPS beats; driven by liver disease portfolio.

Amgen – Revenue increased, driven by strong product sales but faced higher operating expenses.

Novo Nordisk – Robust performance, constrained by supply issues with Wegovy and Ozempic.

Bayer – Mixed results with strong Pharma but weak Crop Science performance.

If you want to receive a complete copy of this report, including top analyst’ firms opinions, please leave a comment below.”

Sabih Beck

Source: Sabih Beck/LinkedIn

Sabih Beck is the Chief Commercial Officer and Co-Founder of Atacana Group. Previously, he was the Oncology/Hematology Franchise Lead at Roche and served as Director of Global Integrated Insights at Novartis.